BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that the Company has secured an additional contract with its first large-scale pharma services customer.

Gene therapy is a massive and swiftly expanding field that could hold promising cures and treatments for several diseases and genetic problems.

Body fat measurement is swiftly becoming a highly sought-after medical diagnostics and lifestyle self-inspection.

Wilmington, Delaware, United States: Ovarian cancer is a relatively uncommon kind of disease that arises from different types of cells inside the ovary, an almond-shaped egg-producing female reproductive organ.

LumiThera Inc announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with Photobiomodulation using the Valeda® Light Delivery System.

Echosens and Novo Nordisk A/S announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis and increase awareness of the disease among patients, healthcare providers and other stakeholders.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical study that is intended to demonstrate the safety of MANTA® Vascular Closure Device ultrasound (U/S) guided closure, without dependence on the pre-procedural depth locator measurements.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets.

ProMIS Neurosciences Inc. is pleased to announce that it has entered into debenture amendments with seven (7) creditors to settle an aggregate of US$7,000,000 Series 1 Preferred Shares (“Series 1 Shares”) of the Company at US$0.10 per share.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 from July 1-3, 2022, at the O2 universum in Prague, Czech Republic.